- Home
- VNDA vs LCTX Comparison
VNDA vs LCTX Comparison
Compare VNDA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- LCTX
- Stock Information
- Founded
- VNDA 2002
- LCTX 1990
- Country
- VNDA United States
- LCTX United States
- Employees
- VNDA N/A
- LCTX N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VNDA Health Care
- LCTX Health Care
- Exchange
- VNDA Nasdaq
- LCTX Nasdaq
- Market Cap
- VNDA 249.4M
- LCTX 274.0M
- IPO Year
- VNDA 2006
- LCTX N/A
- Fundamental
- Price
- VNDA $5.46
- LCTX $1.73
- Analyst Decision
- VNDA Strong Buy
- LCTX Strong Buy
- Analyst Count
- VNDA 2
- LCTX 4
- Target Price
- VNDA $16.50
- LCTX $4.25
- AVG Volume (30 Days)
- VNDA 503.6K
- LCTX 1.9M
- Earning Date
- VNDA 11-05-2025
- LCTX 11-13-2025
- Dividend Yield
- VNDA N/A
- LCTX N/A
- EPS Growth
- VNDA N/A
- LCTX N/A
- EPS
- VNDA N/A
- LCTX N/A
- Revenue
- VNDA $203,467,000.00
- LCTX $10,914,000.00
- Revenue This Year
- VNDA $15.45
- LCTX N/A
- Revenue Next Year
- VNDA $37.82
- LCTX $176.00
- P/E Ratio
- VNDA N/A
- LCTX N/A
- Revenue Growth
- VNDA 11.78
- LCTX 76.43
- 52 Week Low
- VNDA $3.81
- LCTX $0.37
- 52 Week High
- VNDA $5.59
- LCTX $1.83
- Technical
- Relative Strength Index (RSI)
- VNDA 67.52
- LCTX 69.14
- Support Level
- VNDA $5.22
- LCTX $1.64
- Resistance Level
- VNDA $5.48
- LCTX $1.77
- Average True Range (ATR)
- VNDA 0.21
- LCTX 0.11
- MACD
- VNDA 0.06
- LCTX -0.00
- Stochastic Oscillator
- VNDA 90.31
- LCTX 75.00
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.